20951940

Source:http://linkedlifedata.com/resource/pubmed/id/20951940

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0025202, umls-concept:C0035647, umls-concept:C0205179, umls-concept:C0812241, umls-concept:C1999216
pubmed:issue	4
pubmed:dateCreated	2010-10-18
pubmed:abstractText	Unresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase inhibitor PLX4032 that validate oncogene-targeted melanoma therapy.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20951940-18676756, http://linkedlifedata.com/resource/pubmed/commentcorrection/20951940-20823850
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101130617
pubmed:status	PubMed-not-MEDLINE
pubmed:month	Oct
pubmed:issn	1878-3686
pubmed:author	pubmed-author:HerlynMeenhardM, pubmed-author:VillanuevaJessieJ, pubmed-author:VulturAdinaA
pubmed:copyrightInfo	Copyright © 2010 Elsevier Inc. All rights reserved.
pubmed:issnType	Electronic
pubmed:day	19
pubmed:volume	18
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	301-2
pubmed:year	2010
pubmed:articleTitle	BRAF inhibitor unveils its potential against advanced melanoma.
pubmed:affiliation	The Wistar Institute, Philadelphia, PA 19104, USA.
pubmed:publicationType	Journal Article, Comment